Live Webcast:
Now More Than Ever: Implementing the Mycophenolate Risk Evaluation and Mitigation Strategy in Clinical Practice
Mycophenolate is a commonly used immunosuppressant to prevent organ rejection in transplant recipients. It is also used as an immunosuppressant in other disciplines, such as rheumatology. While mycophenolate has been available for decades – it remains the focus of an ongoing FDA Risk Evaluation and Mitigation Strategy (REMS) program due to the high probability of fetal teratogenicity during pregnancy. Congenital malformations in children born to mothers taking mycophenolate have included hearing loss, cleft palate, heart defect, and various other malformations of the face, head, kidneys, limbs, and esophagus.
Currently, the importance of pregnancy planning and/or prevention is even more critical than in previous years. As of August 2023, twenty-two states ban abortion or restrict the procedure earlier in pregnancy than the standard set by Roe v. Wade for the past 50 years, which was overturned by the Supreme Court in 2022. Thus, as the title of this education initiative states — adherence to the mycophenolate REMS (MREMS) program is of paramount importance — now more than ever.
Please join an expert multidisciplinary faculty in a compelling live and on-demand webcast on how to effectively implement MREMS in clinical practice. As a bonus feature, you’ll also be able to participate in an engaging MREMS “Clinical Clues” Escape Room activity to further reinforce the importance of pregnancy planning and/or prevention when using mycophenolate in women of childbearing potential.
Register here:
CMEO Webcast
Live Webcast: Wednesday, November 8th, 2023 at 6:30 pm ET
This activity offers CE credit for:
Nurses (ANCC) 1.0
Pharmacists (ACPE) 1.0
PAs (AAPA) 1.0
Dentists (ADA CERP) 1.0
Psychologists (APA) 1.0
ABIM MOC 1.0
MIPS Improvement Activity
Royal College MOC
Credit Expiration Date: 11/08/2024
By entering your mobile phone number you agree that CME Outfitters can send you periodic text messages about CME/CE activities. This free service is FCC CAN-SPAM compliant. You may update message preferences or unsubscribe at any time. Check your wireless provider for any message and data rates that may apply.
Expert Faculty

Almut G. Winterstein, RPh, PhD, FISPE
Distinguished Professor, Director for CoDES
Department of Pharmaceutical Outcomes and Policy
University Florida

Miae Kim, PharmD, MS, BCPS
Clinical Pharmacy Specialist
Center for Advanced Heart Disease
Brigham and Women’s Hospital
Boston, MA

Dahima Cintron, MD
Rheumatologist
Duke University School of Medicine
Learning Objectives
At the end of this CME/CE activity, participants should be able to:
- Identify the pregnancy and fetal risks related to mycophenolate use.
- Counsel patients of reproductive potential on pregnancy prevention and/or planning during mycophenolate treatment.
- Monitor and report relevant pregnancies to the Mycophenolate Pregnancy Registry.
Financial Support
This activity is supported by an independent educational grant from the Mycophenolate REMS Group. This activity is intended to be fully compliant with the Mycophenolate REMS education requirements issued by the U.S. Food and Drug Administration (FDA).
Target Audience
Transplant medicine specialists, OB/GYNs, surgeons, rheumatologists, dermatologists, immunologists, cardiologists, primary care practitioners (PCPs), nurse practitioners (NPs), physician associates (PAs), nurses, and pharmacists